GhanaTuberculosis profile
Population  2016 28 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 10 (4.6–18) 36 (16–64)
Mortality (HIV+TB only) 5.5 (2.6–9.6) 20 (9.3–34)
Incidence  (includes HIV+TB) 44 (21–75) 156 (75–265)
Incidence (HIV+TB only) 10 (4.7–17) 35 (17–61)
Incidence (MDR/RR-TB)** 0.84 (0.27–1.4) 3 (0.95–5)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1 (0.4–1.6) 17 (6.7–28) 18 (7.1–30)
Males 1.2 (0.45–1.9) 24 (9.5–39) 26 (9.9–41)
Total 2.2 (0.84–3.5) 42 (16–67) 44 (21–75)
TB case notifications, 2016  
Total cases notified 14 675
Total new and relapse 14 167
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 84%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 32% (19–67)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.39 (0.14–0.69)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 2 838 23%
          - on antiretroviral therapy 1 207 43%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  250
(140–370)
Estimated % of TB cases with MDR/RR-TB 1.5% (0.7–2.3) 7% (0.6–13)  
% notified tested for rifampicin resistance 32% 98% 5 359
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 107, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 77, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 85% 14 460
Previously treated cases, excluding relapse, registered in 2015 78% 539
HIV-positive TB cases registered in 2015 75% 2 631
MDR/RR-TB cases started on second-line treatment in 2014 64% 14
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 67
Funding source: 18% domestic, 15% international, 67% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-23 Data: www.who.int/tb/data